Death of a Director

RNS Number : 6500G

Eden Research plc

08 May 2014

 



The following amendment has been made to the 'Death of a Director' announcement released on 8 May 2014 at 16.53 under RNS No6485G. Sir Ben Gill passed away today, Wednesday 8 May 2014.

Eden Research Plc

("Eden" or "Company")

Death of a Director

Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, is saddened to announce the death of Sir Ben Gill, Non-Executive Chairman, who passed away on Wednesday 8 May 2014, aged 64.

Sir Ben joined Eden as Chairman in June 2009. Tom Lupton, Non-Executive Director, will take on the role of Interim Chairman.

Clive Newitt, Managing Director of Eden, said:"Ben will be remembered and missed by all of us at Eden. He was a highly valued Chairman and friend. He provided our Board with insightful and considered advice and was instrumental in steering Eden towards the commercial success that we are now starting to experience. My colleagues and I extend our thoughts and deepest sympathy to his family."

Eden Research plc	www.edenresearch.com
Clive Newitt, Managing Director	Tel: [phone]
Alex Abrey, Chief Financial Officer
W H Ireland Limited	Tel: [phone]
John Wakefield
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]

Notes:

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit www.edenresearch.com 

 

END

 

 

MSCBLGDUXGGBGSI